Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients: Enhancing Technological Innovation and Strengthening the Role of Small Businesses in Meeting Needs of Adolescent Organ Transplant

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 21
Healthy Volunteers: f
View:

• Eligible participants are 10-21 years of age

• Have received a heart transplant and are followed participating pediatric heart transplant centers

• English-speaking or Spanish-speaking

• Own a smart-phone or have access to the mobile app through other devices

• Are willing to receive information through it

• Have a MLVI score of greater than 2.0 over the last year

Locations
United States
Florida
University of Miami, Miller School of Medicine
RECRUITING
Coral Gables
University of Florida
RECRUITING
Gainesville
Joe DiMaggio Children's Hospital
RECRUITING
Hollywood
FSU College of Medicine
NOT_YET_RECRUITING
Tallahassee
Contact Information
Primary
Dipankar Gupta, MD
dgupta@ufl.edu
352-273-5422
Backup
Dalia Lopez-Colon, PhD
dalylc@ufl.edu
352-281-6723
Time Frame
Start Date: 2024-10-01
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 100
Treatments
Experimental: eMocha intervention
Adolescent patients randomized to the use of asynchronous mobile video directly observed therapy (DOT) intervention (eMocha DOT app)
No_intervention: Standard of care
Adolescent patients who continue enhanced goal-setting standard of care
Related Therapeutic Areas
Sponsors
Collaborators: emocha Mobile Health, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Leads: University of Florida

This content was sourced from clinicaltrials.gov